述评 |
|
|
|
|
分子靶向抗肿瘤药物的毒性研究进展 |
娄小娥, 陈敏, 杨波 |
浙江大学药学院药理毒理与生化药学研究所, 浙江杭州 310058 |
|
Research progress in toxicology of molecular targeted anticancer drugs |
LOU Xiao-e, CHEN Min, YANG Bo |
Institute of Pharmacology & Toxicology and Biochemical Pharmaceutics, Zhejiang University, Hangzhou 310058, China |
[1] |
DASSONVILLE O, BOZEC A, FISCHEL J L, et al. EGFR targeting therapies:monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences[J]. Crit Rev Oncol Hemat, 2007,62(1):53-61.
|
[2] |
ZHANG S, LIU X, BAWA-KHALFE T,et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity[J]. Nat Med, 2012,18(11):1639-1942.
|
[3] |
RASCHI E, VASINA V, URSINO M G, et al. Anticancer drugs and cardiotoxicity:insights and perspectives in the era of targeted therapy[J]. J Pharmacol Exp Ther, 2010,125(2):196-218.
|
[4] |
OLSON E M, ABDEL-RASOUL M, MALY J, et al. Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab[J]. Ann Oncol, 2013,24(6):1526-1533.
|
[5] |
ATALLAH E, DURAND J B, KANTARJIAN H, et al. Congestive heart failure is a rare event in patients receiving imatinib therapy[J]. Blood, 2007,110(4):1233-1237.
|
[6] |
FRANCIS J, AHLUWALIA M S, WETZLER M, et al. Reversible cardiotoxicity with tyrosine kinase inhibitors[J]. Clin Adv Hematol Oncol, 2010,8(2):128-132.
|
[7] |
ORPHANOS G S, IOANNIDIS G N, ARDAVANIS A G. Cardiotoxicity induced by tyrosine kinase inhibitors[J]. Acta Oncol, 2009,48(7):964-970.
|
[8] |
SCHMIDINGER M, ZIELINSKI C C, VOGL U M, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma[J]. J Clin Oncol,2008,26(32):5204-5212.
|
[9] |
AI D, BANCHS J, OWUSU-AGYEMANG P, et al. Chemotherapy induced cardiovascular toxicity:beyond anthracyclines[J]. Minerva Anestesiol, 2014,80(5):586-594.
|
[10] |
DOHERTY K R, WAPPEL R L, TALBERT D R, et al. Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes[J]. Toxicol Appl Pharm, 2013,272(1):245-255.
|
[11] |
TRUONG J, YAN A T, CRAMAROSSA G, et al. Chemotherapy-induced cardiotoxicity:detection, prevention and management[J]. Can J Cardiol, 2014,30(8):869-878.
|
[12] |
ALBINI A, PENNESI G, DONATELLI F, et al. Cardiotoxicity of anticancer drugs:the need for cardio-oncology and cardio-oncological prevention[J]. J Natl Cancer Inst, 2010,102(1):14-25.
|
[13] |
FERRERO D, POGLIANI E M, REGE-CAMBRIN G, et al. Corticosteroids can reverse severe imatinib-induced hepatotoxicity[J]. Haematologica, 2006,91(6 Suppl):ECR27.
|
[14] |
REA D, BERGERON A, FIESCHI C, et al. Dasatinib-induced lupus[J]. Lancet, 2008,372(9640):713-714.
|
[15] |
SCHAID D J, SPRAGGS C F, MCDONNELL S K, et al. Prospective validation of HLA-DRB1*07:01 allele carriage as a predictive risk factor for lapatinib-induced liver injury[J]. J Clin Oncol, 2014,32(22):2296-2303.
|
[16] |
YANO Y, NAMBA Y, MORI M, et al. Treatment of non-small-cell lung cancer with erlotinib following gefitinib-induced hepatotoxicity:review of 8 clinical cases[J]. Lung Cancer Int, 2012,2012:354657.
|
[17] |
MANCUSO A, ZAVAGLIA C, BAI F, et al. Letter:sorafenib hepatotoxicity may be enhanced during treatment of advanced hepatocellular carcinoma in HIV-infected patients[J]. Aliment Pharm Therap, 2013,38(11-12):1414-1416.
|
[18] |
SHAH R R, MORGANROTH J, SHAH D R. Hepatotoxicity of tyrosine kinase inhibitors:clinical and regulatory perspectives[J]. Drug Safety, 2013,36(7):491-503.
|
[19] |
BISSELL D M, GORES G J, LASKIN D L, et al. Drug-induced liver injury:mechanisms and test systems[J]. Hepatology, 2001,33(4):1009-1013.
|
[20] |
DU K, WILLIAMS C D, MCGILL M R, et al. The gap junction inhibitor 2-aminoethoxy-diphenyl-borate protects against acetaminophen hepatotoxicity by inhibiting cytochrome P450 enzymes and c-jun N-terminal kinase activation[J]. Toxicol Appl Pharm, 2013,273(3):484-491.
|
[21] |
IKEDA T. Idiosyncratic drug hepatotoxicity:strategy for prevention and proposed mechanism[J]. Curr Med Chem, 2014,22(4):528-537.
|
[22] |
DAHELE M, SENAN S. The role of stereotactic ablative radiotherapy for early-stage and oligometastatic non-small cell lung cancer:evidence for changing paradigms[J]. Cancer Res Treat, 2011,43(2):75-82.
|
[23] |
CHOI M K, HONG J Y, CHANG W J, et al. A phase Ⅱ trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations:implications of sensitive EGFR mutation test[J]. Cancer Chemoth Pharm, 2015,75(6):1229-1236.
|
[24] |
HERBST R S,PRAGER D, HERMANN R,et al. TRIBUTE:a phase Ⅲtrial of erlotinib hydrochloride(OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer[J]. J Clin Oncol, 2005,23(25):5892-5899.
|
[25] |
YAMAGUCHI T, SEKI T, MIYASAKA C, et al. Interstitial pneumonia induced by sorafenib in a patient with hepatocellular carcinoma:an autopsy case report[J]. Oncol Lett, 2015,9(4):1633-1636.
|
[26] |
HARTMANN J T, KOLLMANNSBERGER C, CASCORBI I, et al. A phase I pharmacokinetic study of matuzumab in combination with paclitaxel in patients with EGFR-expressing advanced non-small cell lung cancer[J]. Invest New Drug, 2013,31(3):661-668.
|
[27] |
CARRILLO GARCÍA C. Role of growth/differentiation factor(GDF) 15 in the regulation of embryonic neural precursors[D]. Heidelberg:Ruperto-carola University of Heidelberg, 2008.
|
[28] |
SINGH S, SHI T, DUFFIN R, et al. Endocytosis, oxidative stress and IL-8 expression in human lung epithelial cells upon treatment with fine and ultrafine TiO 2:role of the specific surface area and of surface methylation of the particles[J]. Toxicol Appl Pharm, 2007,222(2):141-151.
|
[29] |
ZUEHLKE R L. Erythematous eruption of the palms and soles associated with mitotane therapy[J]. Dermatologica, 1974,148(2):90-92.
|
[30] |
SIL A, DAS N K.Sorafenib-induced hand-foot syndrome in a patient of renal cell carcinoma[J]. Indian J Pharmacol, 2014,46(3):334-336.
|
[31] |
EDESA W A, ABDELMALEK R R. Efficacy and toxicity of sunitinib in metastatic renal cell carcinoma patients in Egypt[J]. Asian Pac J Cancer P, 2015,16(5):1971-1976.
|
[32] |
WANG G S. Conjecture about hand-foot syndrome in CLASSIC Trial[J]. Iran J Public Health, 2014,43(4):534-534.
|
[33] |
LIN E H, CURLEY S A, CRANE C C, et al. Retrospective study of capecitabine and celecoxib in metastatic colorectal cancer:potential benefits and COX-2 as the common mediator in pain, toxicities and survival[J]. Am J Clin Oncol Canc, 2006,29(3):232-239.
|
[34] |
CARONIA D, MARTIN M, SASTRE J, et al. A polymorphism in the cytidinedeaminase promoter predicts severe capecitabine-induced hand-foot syndrome[J]. Clin Cancer Res, 2011,17(7):2006-2013.
|
[35] |
YAMAMOTO D, YAMAMOTO C, IWASE S, et al. Efficacy of vitamin E treatment for hand-foot syndrome in patients receiving capecitabine[J]. Breast Care, 2010,5(6):415-416.
|
[36] |
BRAIK T, YIM B, EVANS A T, et al. Randomized trial of vitamin B6 for preventing hand-foot syndrome from capecitabine chemotherapy[J]. J Community Support Oncol, 2014,12(2):65-70.
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|